have been linked to AML risk years after your treatment. Alkylating agents keep cells from multiplying and are used in treating many different types of cancers, including lung, breast, and ovarian cancers, as well as leukemia,lymphoma, Hodgkin disease,multiple myeloma...
acute myelogenousleukemiaelderly patients27 patients aged over 60 years with acute myelogenous leukemia (AML) were treated with a chemotherapy regimen consisting of a combination of idarubicin (IDA) and cytosine arabinoside (ARA-C) as the induction regimen, with etoposide and 6-thioguanine added in ...
Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with an incidence of over 20 000 cases per year in the United States alone. Large chromosomal translocations as well as mutations in the genes involved in hematopoietic prolifer
Intensive induction treatment of acute myelocytic leukemia Proc AACR ASCO, 15 (1974), p. 178 (Abstr) Google Scholar 3 OR McIntyre, K Rai, O Glidewell, JF Holland Polyriboinosinic: polyribocytidylic acid as an adjunct to remission maintenance therapy in acute myelogenous leukemia WD Terry, D ...
Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells ... Summary. A 20-year-old woman with high-risk acute myelogenous leukaemia was transplanted with granulocyte colony stimulating factor (G-CSF)-mobi...
Poor prognosis acute myelogenous leukemia: 1 – response to treatment with high dose cytarabine/mitoxantrone/ethyol @ (Amifostine) This is the third paper in a series which describes a new remission induction regimen for patients with 'poor prognosis' acute myelogenous leukemia (AML). ... HD Pre...
Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML. These included several targeted therapies like venetoclax, FLT3 inhi
To improve treatment results for children with de novo acute myeloid leukemia (AML), we introduced a novel protocol, Taiwan Pediatric Oncology Group-AML-97A, for AML other than acute promyelocytic leukemia (APL), for which modified conventional protocols
Secondary acute non-lymphoblastic leukemia in two children following treatment with a cis-diamminedichloroplatinum-II-based regimen for osteosarcoma based regimen: acute monomyelogenous leukemia (M4) with a normal female karyotype in one and acute myelogenous leukemia (M2) with t (8,21) in the ....
Treatment of childhood acute myelogenous leukemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages: short- and long-term effects Leukemia 2000 (in press Hurwitz CA, Krance R, Schell MJ, Santana VM, Brenner MK, Ribeirio R, Roberts WM, Mahmoud H, Belt ...